Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

If you own or are considering buying pharma laggards Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and Merck (NYSE: ...

“By accelerating the production and sharing of trustworthy data, as we are doing at MassCPR, we can empower the public with ...

The health care industry took a beating in President Donald Trump’s tax law, which slashed $1.1 trillion from Medicaid and ...

An internal memo written by the Food and Drug Administration’s top vaccine regulator offers a concerning glimpse into the ...

The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to ...

Protego Biopharma is poised to start pivotal trials of its amyloid light-chain (AL) amyloidosis drug candidate, thanks to a ...

Mixed options sentiment in Pfizer (PFE), with shares up 30c, or 1.15%, near $26.00. Options volume roughly in line with average with 139k ...

Argenta announced on Friday it will execute a strategic consolidation of its operations within the United States, a move that “will begin a phased ramp-down of activities at its Fort Dodge facility,” ...

AI-driven discovery, EHR-based real-world evidence, and synthetic patient modeling are rapidly reshaping drug repurposing, reducing development timelines, expanding therapeutic applications, and ...

Vikram Punia underscores the growing India–Russia–EAEU pharmaceutical axis as a strategic opportunity for Indian firms entering expanding Eurasian healthcare markets ...